protein
microarray
highthroughput
technolog
use
increasingli
translat
research
seek
appli
basic
scienc
find
enhanc
human
health
addit
assess
protein
level
posttransl
modif
signal
pathway
patient
sampl
protein
microarray
aid
identif
potenti
protein
biomark
diseas
infect
perspect
differ
type
fulllength
protein
microarray
use
translat
research
review
specif
studi
employ
microarray
present
highlight
potenti
find
solut
real
clinic
problem
final
criteria
consid
develop
nextgener
protein
microarray
provid
blbc
basallik
breast
cancer
ci
confid
interv
dualspecif
tyrosin
phosphorylationregul
kinas
gpcr
gcoupl
protein
receptor
hpv
human
papillomaviru
ivd
vitro
diagnost
mmtv
mous
mammari
tumor
viru
mtb
mycobacterium
tuberculosi
mtor
mammalian
target
rapamycin
mv
membran
vesicl
nappa
nucleic
acid
programm
protein
array
npm
natur
protein
microarray
pf
plasmodium
falciparum
phenylalanin
residu
rcpa
reversecaptur
protein
array
rppa
reversephas
protein
array
sle
system
lupu
erythematosu
type
diabet
wherea
human
genom
proteincod
gene
estim
least
differ
proteoform
result
polymorph
ptm
altern
splice
protein
act
alon
instead
reli
complex
interact
protein
molecul
propag
signal
lead
specif
cellular
respons
given
breadth
protein
speci
highthroughput
method
essenti
gain
comprehens
understand
proteom
popular
highthroughput
technolog
studi
proteom
protein
microarray
simpli
defin
protein
microarray
microscop
tool
display
hundr
thousand
differ
protein
fix
substrat
highdens
array
format
queri
analyz
simultan
protein
microarray
distinguish
protein
display
method
yeast
phage
display
ident
protein
associ
array
address
known
advanc
protein
microarray
help
tackl
routin
challeng
proteom
technolog
includ
low
protein
abund
complic
assay
procedur
difficulti
modul
assay
environ
low
sensit
lowthroughput
analysi
protein
addit
basic
research
protein
microarray
becom
use
translat
research
aim
translat
find
fundament
research
clinic
practic
meaning
health
outcom
translat
research
often
includ
use
clinic
sampl
intent
discov
valid
potenti
biomark
aid
diagnosi
prognosi
stratif
treatment
patient
order
achiev
adequ
statist
power
biomark
discoveri
valid
analys
ten
hundr
differ
clinic
sampl
often
requir
due
high
biolog
variat
among
patient
expens
associ
analyz
mani
sampl
part
respons
modest
adopt
protein
microarray
translat
research
exampl
product
purif
thousand
differ
protein
much
complex
produc
dna
oligonucleotid
gene
microarray
addit
protein
microarray
must
achiev
tight
toler
high
reproduc
within
batch
order
discern
subtl
differ
across
clinic
sampl
new
strategi
improv
manufactur
techniqu
led
rapid
increas
applic
protein
microarray
translat
research
variou
type
protein
microarray
use
translat
research
includ
protein
fragment
array
peptid
array
display
random
amino
acid
sequenc
known
sequenc
sequenc
deriv
predict
protein
recent
hybrid
system
use
bacteriophag
display
barcod
peptid
human
virus
screen
antibodi
target
viral
peptidom
indic
histori
infect
compar
standard
protein
microarray
employ
purifi
fulllength
protein
protein
fragment
peptid
microarray
easier
produc
due
smaller
size
simpler
structur
protein
fragment
array
also
use
antibodi
fragment
lack
fc
domain
probe
specif
antigen
patient
sampl
flexibl
peptid
microarray
allow
incorpor
nonnatur
amino
acid
ptm
specif
site
use
unnatur
peptid
sequenc
howev
bind
epitop
especi
conform
one
may
lost
protein
fragment
peptid
microarray
given
divers
protein
microarray
applic
limit
scope
perspect
use
protein
microarray
display
fulllength
protein
articl
first
outlin
differ
fulllength
protein
microarray
avail
well
advantag
disadvantag
tabl
present
translat
research
studi
cancer
autoimmun
diseas
infecti
diseas
employ
fulllength
protein
microarray
discuss
role
protein
microarray
drug
discoveri
vitro
diagnost
ivd
test
last
provid
criteria
consid
design
nextgener
protein
microarray
planar
protein
microarray
display
fulllength
protein
appli
translat
research
classifi
three
main
type
base
protein
produc
array
refer
purifi
natur
cellfre
express
protein
microarray
fig
tabl
popular
microarray
format
purifi
protein
microarray
protein
express
heterolog
system
insect
cell
escherichia
coli
yeast
protein
purifi
plate
format
via
fusion
tag
subsequ
print
slide
purifi
protein
microarray
origin
use
build
yeast
proteom
microarray
contain
orf
sinc
employ
variou
protein
function
antibodi
biomark
discoveri
studi
current
comprehens
purifi
protein
array
huprot
tm
human
proteom
microarray
manufactur
arrayit
corpor
cdi
laboratori
array
protein
differ
gene
cover
human
genom
repres
differ
splice
isoform
howev
disadvantag
purifi
protein
microarray
approach
includ
expens
time
requir
express
purif
thousand
protein
ii
challeng
express
purifi
larg
protein
kda
membran
protein
iii
short
shelf
life
iv
possibl
incorrect
protein
fold
activ
protein
express
differ
host
milieu
eg
human
protein
express
e
coli
dri
follow
array
product
unlik
purifi
protein
array
employ
heterolog
system
produc
protein
natur
protein
microarray
npm
print
use
human
cell
lysat
tissu
lysat
bodili
fluid
eg
serum
contain
natur
express
protein
like
fold
activ
ptm
vivo
time
sampl
collect
protein
print
complet
lysat
fraction
use
multidimension
liquidbas
separ
techniqu
captur
array
surfac
specif
antibodi
translat
applic
differ
depend
fraction
state
lysat
protein
captur
slide
npm
fraction
sampl
often
probe
serum
use
studi
immun
respons
variou
cancer
alter
antigen
ie
phosphoryl
glycosyl
protein
antibodi
target
must
subsequ
identifi
often
done
mass
spectrometri
sampl
fraction
also
assist
analys
specif
protein
class
exampl
membran
glycosyl
protein
unfraction
npm
also
known
revers
phase
protein
array
rppa
lysat
array
revers
phase
lysat
array
lysat
array
probe
antibodi
recogn
key
signal
protein
modifi
form
help
determin
specif
signal
pathway
dy
regul
diseas
infect
may
indic
potenti
therapeut
option
moreov
numer
patient
control
sampl
analyz
simultan
rppa
primari
advantag
rppa
abl
discern
dynam
posttransl
event
eg
ptm
greatli
affect
protein
interact
within
complex
signal
network
inform
determin
analyz
gene
express
protein
level
alon
altern
reversecaptur
protein
array
rcpa
coat
antibodi
captur
protein
express
vivo
eg
tumor
antigen
use
probe
autoantibodi
serolog
sampl
unlik
rppa
analyz
one
protein
across
mani
patient
sampl
rcpa
gener
use
studi
multipl
protein
within
one
sampl
disadvantag
fraction
unfraction
rppa
captur
rcpa
npm
includ
relianc
highqual
antibodi
specif
pathway
ofinterest
may
avail
ii
lowabund
target
protein
may
difficult
detect
iii
protein
may
lose
activ
purif
print
storag
cellfre
protein
microarray
develop
avoid
challeng
relat
protein
captur
purif
array
product
describ
section
therefor
cellfre
protein
microarray
use
pcrgener
dna
fragment
plasmid
cdna
express
protein
cellfre
express
system
transcrib
translat
genesofinterest
variou
express
system
commerci
avail
includ
lysat
e
coli
wheat
germ
insect
cell
rabbit
reticulocyt
human
cell
cellfre
protein
microarray
includ
protein
situ
array
dna
array
protein
array
nucleic
acid
programm
protein
array
nappa
situ
puromycincaptur
array
unpurifi
protein
array
develop
davi
et
al
follow
vitro
transcript
translat
typic
requir
h
express
protein
captur
situ
captur
antibodi
molecul
unpurifi
cellfre
microarray
use
captur
agent
instead
lysat
contain
express
proteinofinterest
spot
directli
onto
nitrocellulos
substrat
assumpt
coprint
lysat
similar
background
featur
featur
unpurifi
cellfre
protein
microarray
success
appli
immun
profil
antibodi
biomark
discoveri
infecti
diseas
addit
aforement
applic
nappa
also
use
studi
proteinprotein
interact
ptm
mani
advantag
use
cellfre
express
approach
includ
abil
express
protein
appropri
express
milieu
time
experi
cell
lysat
includ
chaperon
protein
also
allow
proteinsofinterest
express
fold
maintain
physiolog
compat
buffer
time
translat
experi
thu
significantli
reduc
likelihood
unfold
denatur
dri
cellfre
express
array
costeffect
requir
protein
purif
print
dna
ie
dna
array
protein
array
nappa
result
stabl
array
longer
shelf
life
proteinbas
microarray
array
easili
made
high
throughput
thousand
differ
protein
display
standards
microscop
slide
ie
mm
exampl
nappa
use
routin
densiti
protein
per
slide
increas
use
nanowel
final
immun
respons
diseas
may
recogn
linear
conform
epitop
thu
biomark
screen
use
protein
fold
denatur
like
valu
display
type
epitop
nappa
amen
studi
fold
denatur
protein
make
possibl
identifi
autoantibodi
biomark
epitop
would
otherwis
buri
healthi
homeostasi
also
disadvantag
cellfre
approach
unpurifi
protein
microarray
protein
function
may
easili
assay
spot
mixtur
differ
molecul
ii
lysat
allow
dri
nitrocellulos
surfac
print
may
affect
protein
fold
activ
iii
serolog
antibodi
react
print
lysat
spot
e
coli
lysat
use
type
cellfre
microarray
nonspecif
bind
compon
cellfre
express
system
array
matrix
may
occur
howev
nonspecif
interact
larg
remov
sever
wash
step
leav
behind
lysat
compon
level
much
lower
proteinofinterest
consist
across
featur
bigger
theoret
concern
lysat
protein
also
human
may
interact
specif
captur
proteinsofinterest
display
protein
complex
therefor
find
confirm
subsequ
studi
also
worth
note
degre
known
ptm
occur
proteinofinterest
express
cell
lysat
notabl
phosphoryl
human
cellfre
express
system
abovedescrib
method
typic
employ
microscop
slide
substrat
howev
beadbas
array
offer
altern
approach
frequent
use
biomark
valid
develop
ivd
test
particularli
use
number
proteinsofinterest
modest
number
clinic
specimen
high
fig
howev
recent
advanc
approach
enabl
analys
greater
number
protein
beadbas
microarray
address
target
protein
embed
color
specif
bound
bead
luminex
xmap
r
technolog
bead
barcod
use
two
fluoresc
dye
mix
appropri
ratio
differ
color
bead
avail
color
bead
n
combin
four
fluoresc
dye
also
develop
higher
throughput
analys
exampl
antigensofinterest
differ
colorco
bead
incub
serolog
sampl
captur
antibodi
serolog
sampl
bound
fluoresc
label
secondari
antibodi
two
read
take
place
analys
bead
color
identifi
associ
antigen
ii
fluoresc
secondari
antibodi
indic
abund
serolog
antibodi
specif
bound
antigen
merit
beadbas
assay
includ
high
sensit
wide
dynam
rang
excel
reproduc
eas
autom
moreov
beadbas
assay
approv
clinic
use
includ
lifecod
r
lifescreen
delux
hla
antibodi
assay
immucor
gti
diagnost
inc
bioplex
r
hiv
agab
biorad
laboratori
howev
product
bind
individu
protein
uniqu
color
bead
costli
especi
larg
number
protein
proteom
biomark
discoveri
valid
pipelin
often
divid
three
consecut
phase
includ
identifi
candid
biomark
ie
discoveri
verifi
biomark
independ
sampl
cohort
final
valid
biomark
clinic
applic
fig
translat
phase
research
refer
first
two
step
biomark
discoveri
verif
especi
import
screen
mani
differ
candid
protein
possibl
avoid
miss
good
marker
thu
planar
protein
microarray
excel
tool
discoveri
abil
display
ten
thousand
differ
protein
easili
address
configur
later
phase
fewer
candid
protein
need
test
beadbas
protein
microarray
elisa
assay
ideal
analyz
mani
patient
sampl
quickli
breast
cancer
second
common
caus
cancerrel
mortal
women
unit
state
america
earlier
cancer
diagnosi
improv
patient
prognosi
current
mammographi
standard
screen
method
earli
detect
breast
cancer
howev
even
though
test
higher
sensit
realworld
sensit
mammographi
report
low
reflect
variat
radiologist
assess
tumor
subtyp
patient
age
patient
complianc
breast
densiti
therefor
identif
circul
autoantibodi
biomark
potenti
fill
clinic
nich
noninvas
inexpens
rapid
approach
earli
diagnosi
breast
cancer
could
complement
imag
studi
anderson
et
al
identifi
autoantibodi
biomark
breast
cancer
screen
sera
earli
stage
breast
cancer
patient
stage
iiii
use
nappa
protein
microarray
array
contain
uniqu
human
protein
includ
breast
cancer
protein
preselect
bioinformat
data
mine
gcoupl
protein
receptor
gpcr
kinas
transcript
factor
use
three
independ
sampl
set
total
case
total
agematch
healthi
control
potenti
autoantibodi
biomark
identifi
verifi
sensit
specif
blind
condit
biomark
could
use
earli
detect
breast
cancer
futur
ladd
et
al
analyz
dynam
interact
tumor
antigen
circul
autoantibodi
breast
cancer
develop
progress
npm
prepar
use
lysat
mous
mammari
tumor
viru
mmtv
neu
breast
cancer
mous
model
human
breast
cancer
cell
line
mmtvneu
mous
model
protein
array
probe
sera
breast
cancer
mous
model
human
breast
cancer
cell
line
protein
array
probe
sera
human
patient
recent
diagnos
soontob
diagnos
breast
cancer
two
glycolysi
splicesom
autoantibodi
signatur
identifi
auc
confid
interv
ci
ci
respect
although
signatur
need
valid
larger
patient
popul
determin
whether
use
diagnos
breast
cancer
clinic
set
studi
provid
compel
evid
tumor
autoantibodi
gener
earli
develop
breast
cancer
basallik
breast
cancer
blbc
aggress
type
breast
cancer
rel
poor
detect
rate
screen
mammographi
use
individu
agematch
plasma
sampl
polish
breast
cancer
studi
wang
et
al
execut
largest
unbias
discoveri
autoantibodi
associ
blbc
use
nappa
protein
microarray
antigen
pair
patient
control
seven
hundr
fortyeight
antigen
identifi
potenti
target
autoantibodi
diseas
discoveri
phase
print
independ
array
screen
use
independ
sampl
set
blbc
case
control
final
antigen
verifi
use
elisa
pair
blbc
patient
control
panel
verifi
autoantibodi
discrimin
blbc
sampl
control
sensit
specif
blind
condit
biomark
great
potenti
use
earli
diagnos
blbc
thu
improv
patient
prognosi
viral
infect
close
associ
type
cancer
includ
human
papillomaviru
hpv
cervic
cancer
therefor
detect
antibodi
viral
protein
clinic
set
use
properli
diagnos
treat
patient
infect
virus
caus
cancer
waterbo
et
al
develop
beadbas
assay
measur
serolog
antibodi
hpv
protein
coupl
glutathion
stransferas
fusion
hpv
protein
glutathioneco
bead
seven
hundr
fiftysix
sera
pair
cervic
cancer
case
control
test
assay
identifi
associ
cervic
cancer
antibodi
viral
protein
two
hpv
type
statist
signific
pvalu
high
correl
elisa
multiplex
serolog
assay
requir
minim
sampl
volum
l
serum
antigen
show
greater
sensit
gstcaptur
elisa
moreov
assay
sensit
serum
dilut
dynam
rang
order
magnitud
coeffici
variat
assay
reproduc
r
although
previous
known
cervic
cancer
patient
could
develop
antibodi
protein
studi
demonstr
util
multiplex
beadbas
serolog
assay
biomark
verif
rhabdomyosarcoma
frequent
soft
tissu
tumor
children
often
driven
part
dysregul
prosurviv
target
rapamycin
mtor
pathway
sinc
children
diagnos
rhabdomyosarcoma
respond
standard
chemotherapi
treatment
petricoin
et
al
appli
rppa
map
phosphoproteom
network
within
pathway
object
identifi
better
treatment
option
nonrespond
lyse
microdissect
tumor
cell
patient
print
directli
onto
planar
surfac
probe
antibodi
specif
protein
phosphoprotein
pathway
higher
level
phosphoryl
protein
reflect
pathway
activ
significantli
associ
poor
overal
diseasefre
surviv
childhood
rhabdomyosarcoma
mtor
inhibitor
ie
rapamycin
analogu
abl
profoundli
reduc
tumor
growth
mous
xenograft
suggest
administr
mtor
inhibitor
patient
high
mtor
pathway
activ
may
result
favor
chemotherapi
respons
improv
cancer
prognosi
result
studi
describ
section
illustr
valu
protein
microarray
find
circul
auto
antibodi
biomark
earli
cancer
detect
well
map
protein
signal
network
improv
cancer
treatment
thu
underscor
import
translat
research
protein
microarray
employ
better
understand
autoimmun
diseas
immun
system
destroy
healthi
cell
tissu
individu
multipl
sclerosi
common
autoimmun
disord
affect
cn
caus
symptom
includ
fatigu
dizzi
pain
spastic
depress
cognit
impair
bladderbowel
problem
report
million
peopl
worldwid
multipl
sclerosi
develop
new
biomark
would
help
diagnos
predict
onset
multipl
sclerosi
address
need
ayoglu
et
al
screen
sera
multipl
sclerosi
patient
use
purifi
protein
microarray
contain
protein
fragment
uniqu
protein
gener
human
protein
atla
project
among
reactiv
autoantibodi
initi
identifi
prioriti
target
verifi
larg
sampl
cohort
n
use
beadbas
assay
fifti
one
autoantibodi
show
differenti
respons
eight
subtyp
multipl
sclerosi
work
demonstr
valu
protein
microarray
find
potenti
multipl
sclerosi
biomark
support
valid
biomark
larger
popul
also
highlight
complement
role
planar
beadbas
protein
array
proteom
biomark
discoveri
valid
pipelin
fig
autoantibodi
serolog
inflammatori
factor
ie
cytokin
chemokin
growth
factor
may
inhibit
immun
involv
inflammatori
autoimmun
diseas
price
et
al
prepar
purifi
protein
microarray
contain
human
cytokin
chemokin
well
antigen
relat
autoimmun
diseas
author
test
patient
system
lupu
erythematosu
sle
patient
control
addit
confirm
known
autoantibodi
price
et
al
identifi
new
sle
autoantibodi
target
tnf
furthermor
observ
autoantibodi
reactiv
b
cellactiv
factor
may
associ
sle
sever
addit
studi
use
independ
sampl
cohort
warrant
valid
potenti
autoantibodi
sle
type
diabet
chronic
autoimmun
diseas
significantli
affect
glucos
metabol
character
immun
destruct
insulinproduc
cell
pancreat
islet
caus
complex
incomplet
understood
interact
individu
genet
background
environment
factor
immun
system
unit
state
alon
million
peopl
live
result
billion
associ
healthcar
cost
per
year
cdc
diabet
statist
report
econom
cost
diabet
unit
state
therefor
clear
biomark
earli
predict
diagnosi
urgent
need
miersch
et
al
perform
proteomewid
screen
serolog
autoantibodi
biomark
use
nappa
protein
microarray
contain
human
protein
ten
potenti
autoantibodi
biomark
identifi
cohort
case
control
valid
cohort
case
control
cohort
case
control
among
autoantibodi
dualspecif
tyrosin
phosphorylationregul
kinas
valid
use
luciferas
immuno
precipit
system
assay
sensit
specif
combin
known
antigen
gener
higher
auc
compar
auc
alon
respect
recent
followup
better
understand
environment
trigger
bian
et
al
fabric
viral
proteom
microarray
contain
viral
protein
differ
virus
use
nappa
technolog
analyz
antibodi
respons
patient
agegend
match
patient
without
approach
appear
provid
reliabl
measur
histor
infect
antivir
antibodi
respons
common
virus
correl
well
known
viral
infect
rate
epidemiolog
studi
interestingli
viral
infect
close
associ
ci
epsteinbarr
viru
particularli
younger
patient
studi
demonstr
potenti
valu
immunoproteom
better
understand
role
viral
infect
chronic
diseas
studi
probe
subset
human
proteom
despit
result
compel
comprehens
human
proteom
collect
doubt
expand
number
potenti
antibodi
biomark
autoimmun
diseas
could
use
diagnos
stratifi
treat
patient
compar
tradit
analyt
technolog
eg
elisa
protein
microarray
offer
comprehens
systemat
approach
profil
humor
immun
respons
numer
infecti
pathogen
high
sensit
specif
zhu
et
al
prepar
protein
microarray
purifi
protein
sar
coronaviru
sarscov
five
addit
coronavirus
screen
sera
sar
sarscov
patient
respiratori
ill
patient
healthcar
profession
multiantibodi
signatur
verifi
two
independ
cohort
canada
sar
patient
healthi
sensit
specif
china
sar
patient
healthi
sensit
specif
result
protein
microarray
elisa
data
exhibit
good
correl
predict
sar
infect
patient
fever
sar
outbreak
china
data
demonstr
viralbas
protein
microarray
capac
find
specif
antibodi
associ
viral
infect
mycobacterium
tuberculosi
mtb
bacteri
pathogen
infect
approxim
onethird
world
popul
infect
individu
eventu
develop
activ
tuberculosi
addit
caus
seriou
health
complic
eg
organ
joint
damag
activ
tuberculosi
result
death
percentag
activ
case
significantli
higher
develop
countri
limit
access
resourc
medic
thu
comprehens
studi
tuberculosishost
interact
invalu
understand
mechan
infect
develop
rapid
diagnost
test
mtb
kunnathvelayudhan
et
al
evalu
humor
respons
entir
tuberculosi
proteom
across
patient
tb
nontb
diseas
use
unpurifi
protein
microarray
result
reveal
mtb
proteom
recogn
bodi
immun
system
high
proport
produc
antibodi
target
membraneassoci
extracellular
protein
bacteria
addit
activ
tb
patient
show
variabl
respons
protein
mtb
proteom
correl
bacillari
burden
twelv
protein
previous
identifi
antigen
b
cell
cell
deng
et
al
also
evalu
humor
antibodi
respons
mtb
proteom
howev
analyz
immun
respons
patient
activ
mtb
recov
patient
follow
antibiot
treatment
use
purifi
protein
microarray
fourteen
antibodi
mtb
antigen
discrimin
activ
recov
patient
identifi
subsequ
verifi
two
independ
cohort
cohort
activ
tb
recov
tb
cohort
activ
tb
recov
tb
pvalu
pradosrosal
et
al
assess
vaccin
potenti
mtb
membran
vesicl
mv
shown
secret
mtb
mous
model
appli
sera
obtain
mice
immun
mv
challeng
bacillu
vaccin
cellfre
express
mtb
proteom
microarray
ie
nappa
bacillu
vaccin
serv
neg
control
experi
sinc
mv
result
indic
dozen
humor
antibodi
specif
induc
mous
immun
mv
mtb
target
antigen
primarili
membran
cell
wall
protein
studi
gener
evid
mtb
mv
could
use
develop
vaccin
mtb
infect
despit
larg
variat
studi
aim
sampl
origin
studi
design
microarray
platform
purifi
vs
nappa
vs
unpurifi
well
geograph
locat
sampl
acquisit
interest
see
espa
shown
top
hit
kunnathvelayudhan
pradosrosal
studi
espb
found
kunnathvelayudhan
deng
studi
function
annot
cellwal
cellprocess
protein
tuberculist
databas
http
tuberculistepflch
moreov
diagnost
biomark
tb
previous
shown
sensit
specif
chines
patient
patient
activ
pulmonari
tuberculosi
control
subject
view
studi
might
investig
target
vaccin
develop
wherea
may
good
predict
marker
therapeut
treatment
tb
patient
plasmodium
falciparum
pf
protozoan
parasit
transmit
femal
anophel
mosquito
caus
fatal
form
malaria
human
high
complic
mortal
immun
system
protect
host
repeat
malaria
infect
potenti
exploit
therapeut
treatment
malaria
patient
crompton
et
al
prepar
unpurifi
protein
microarray
contain
pf
protein
analyz
humor
antibodi
respons
individu
mali
malaria
season
four
hundr
ninetyon
immunogen
protein
recogn
immun
system
confirm
previou
studi
pfexpos
kenyan
adult
use
unpurifi
cellfre
express
protein
microarray
result
reveal
antibodi
respons
pf
protein
significantli
increas
children
malaria
season
level
antibodi
decreas
author
hypothes
decreas
level
like
due
antibodi
halflif
find
biomark
indic
malaria
infect
helb
et
al
screen
ugandan
children
antibodi
target
pf
antigen
unpurifi
protein
microarray
result
reveal
threeantibodi
biomark
signatur
put
exonucleas
accur
classifi
individu
day
postinfect
auc
data
verifi
yet
howev
abil
estim
pf
exposur
extrem
use
effect
control
elimin
malaria
unfortun
biomark
candid
crompton
et
al
helb
et
al
easili
compar
due
differ
gene
annot
use
studi
demonstr
highdens
protein
microarray
appli
profil
dynam
host
immun
respons
regard
viral
infect
cycl
parasit
infect
identifi
novel
diagnost
antibodi
biomark
identifi
potenti
vaccin
target
host
protect
fifti
prescrib
drug
target
membran
protein
due
crucial
role
molecular
bind
signal
transport
ion
regul
thu
highthroughput
membran
protein
array
platform
significantli
facilit
drug
screen
process
fang
et
al
demonstr
feasibl
array
print
three
extract
gpcr
protein
adrenerg
receptor
neurotensin
receptor
dopamin
receptor
modifi
slide
bind
fluoresceinconjug
antagonist
cgp
ici
neurotensin
correspond
receptor
betaadrenerg
receptor
neurotensin
receptor
detect
membran
protein
array
develop
hong
et
al
illustr
screen
abil
array
use
mixtur
fluoresceinlabel
ligand
array
display
ten
gpcr
receptor
protein
sandwichbas
competit
assay
although
throughput
array
still
quit
low
feasibl
approach
show
promis
recent
highthroughput
capabl
membran
protein
array
limit
detergentbas
protein
extract
mammalian
cell
subsequ
array
fabric
hu
et
al
develop
novel
highthroughput
strategi
exploit
infect
machineri
util
herp
virus
follow
molecular
clone
transfect
mammalian
cell
infect
herp
viru
membran
proteinsofinterest
display
larg
secret
spheric
herpesviru
virion
virion
purifi
simpl
sucros
gradient
print
onto
nitrocellulos
membran
slide
activ
singlepass
multipass
transmembran
protein
virion
display
array
confirm
use
antibodi
stain
ligand
interact
assay
protein
microarray
also
use
screen
effect
small
molecul
proteinprotein
interact
exampl
glycoprotein
play
critic
function
entri
hiv
viru
host
cell
bind
tcell
receptor
conserv
bind
pocket
phenylalanin
residu
suggest
play
import
role
alter
receptor
bind
character
purifi
protein
array
queri
seven
gfptag
analog
contain
deriv
differ
size
steric
conform
bind
analog
assess
use
rabbit
antigfp
antibodi
antirabbit
secondari
antibodi
compar
wildtyp
receptor
interact
becam
stronger
modifi
hydrophob
group
data
point
toward
new
direct
develop
inhibitor
assay
reagent
hiv
treatment
result
demonstr
protein
microarray
capabl
screen
antibodi
membran
protein
small
compound
drug
discoveri
highthroughput
way
major
ivd
test
implement
protein
array
use
diagnos
autoimmun
infecti
diseas
advanc
ivd
test
use
beadbas
array
includ
athena
r
test
system
bioplex
r
multiplex
platform
ivd
test
autoimmun
diseas
includ
system
rheumatoid
diseas
vascul
thyroid
diseas
celiac
diseas
antiphospholipid
syndrom
ivd
test
infecti
diseas
includ
epsteinbarr
viru
herp
simplex
viru
torch
treponemapallidum
randox
laboratori
develop
fulli
autom
planarbas
evidencebiochip
analyz
system
capabl
analyz
test
per
hour
varieti
kit
cardiac
cerebr
cytokin
endocrin
metabol
syndrom
tumor
marker
commerci
avail
moreov
immunoassay
array
test
common
drug
abus
ce
mark
fda
approv
use
ivd
devic
despit
tremend
effort
spent
discoveri
biomark
variou
cancer
cancer
biomark
fdaapprov
ivd
test
one
test
beadbas
test
aspira
lab
tm
combin
five
biomark
ie
microglobulin
ca
apolipoprotein
prealbumin
transferrin
assess
likelihood
ovarian
mass
malign
prior
surgeri
test
employ
score
correspond
likelihood
malign
complet
human
genom
project
averag
year
newli
discov
biomark
becom
part
ivd
test
market
trend
biomarkerbas
ivt
test
amplion
inc
wwwamplioncom
anticip
biomark
approv
ivd
test
within
next
year
protein
microarray
increas
understand
protein
function
protein
signal
immun
respons
infect
diseas
futur
studi
employ
wellestablish
novel
platform
address
current
limit
protein
microarray
exampl
protein
microarray
use
studi
hand
common
wellstudi
ptm
eg
phosphoryl
glycosyl
ampyl
howev
like
futur
platform
adapt
analyz
addit
modif
shown
affect
protein
activ
locat
degrad
stabil
homeostat
interact
protein
microarray
also
unabl
provid
kinet
affin
proteinprotein
interact
highthroughput
manner
comprehens
character
transient
stabl
proteinprotein
interact
may
help
identifi
critic
decis
protein
within
complex
interact
network
could
use
therapeut
target
diseas
next
gener
protein
microarray
take
follow
consider
protein
express
activ
ii
cost
easeofus
flexibl
iii
sensit
dynam
rang
assay
iv
reproduc
critic
factor
fulllength
protein
microarray
includ
protein
express
activ
describ
protein
microarray
technolog
use
heterolog
system
express
human
protein
may
result
fulllength
function
product
mammalianbas
express
system
offer
excel
altern
previou
studi
human
hela
cell
lysat
vitro
transcript
translat
system
success
express
rate
use
fulllength
human
protein
variou
size
function
compar
e
coli
hela
cellproduc
protein
show
function
proteinprotein
interact
ptm
ie
ampyl
assay
recogn
serolog
antibodi
addit
hela
cell
lysat
lysat
human
erythroleukem
cell
chines
hamster
ovari
cell
also
abl
produc
human
protein
high
cost
fulllength
protein
microarray
major
limit
make
platform
standard
laboratori
tool
especi
highdens
proteom
microarray
protein
microarray
afford
particularli
relev
translat
research
due
requir
ten
hundr
differ
sampl
use
differ
cellfre
method
produc
protein
microarray
offer
advantag
includ
low
cost
dna
product
qualiti
control
ii
fresh
protein
product
hour
iii
dna
array
stabl
month
room
temperatur
iv
custom
array
protein
made
cdna
avail
access
wide
varieti
cdna
becom
easier
cheaper
plasmid
repositori
gener
program
protein
structur
initi
import
aspect
protein
microarray
consider
sensit
dynam
rang
relev
acquir
inform
lowabund
biomark
protein
biolog
sampl
accur
quantifi
chang
protein
differ
condit
respect
exampl
zhang
et
al
develop
plasmon
gold
chip
spot
purifi
protein
detect
autoantibodi
use
nearinfrar
fluorescenceenhanc
detect
two
three
order
higher
sensit
glass
slide
uml
plasmon
array
autoantibodi
three
antigen
insulin
distinguish
type
diabet
final
protein
microarray
highli
reproduc
robust
particularli
use
translat
research
clinic
assay
reproduc
significantli
improv
autom
array
process
sampl
incub
signal
readout
screen
clinic
sampl
highdens
protein
microarray
use
autom
station
result
intraand
interreproduc
r
protein
microarray
increas
understand
proteom
network
regard
normal
homeostasi
diseas
infect
technolog
advanc
particularli
area
list
contribut
protein
microarray
drug
screen
biomark
discoveri
improv
patient
care
project
fund
earli
detect
research
network
startup
grant
nation
center
protein
scienc
phoenix
center
beij
author
declar
conflict
interest
